When federal regulators last week approved Digene Corp.'s cervical cancer test as a primary screening tool for women over 30, they catapulted what had been a follow-up test into direct competition ...
NEW YORK, Jan 12 (Reuters) - Digene Corp's new chief executive officer said on Friday the company could not afford to remain "a one-product company" and would aim to disclose a strategy of moving ...
Shares of Digene Corp. jumped 10 percent yesterday after the Gaithersburg company won support from a Food and Drug Administration advisory committee to expand use of its DNA-based test for cervical ...
“Finding a cure for cancer” is synonymous in our society with the ultimate in success. And yet Digene (DIGE $37), which sells a test that could eradicate cervical cancer, meets with tepid enthusiasm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback